Key Highlights
- Intelligent Bio Solutions counted over 480 active customer accounts as of its fiscal first quarter ended September 30, 2025, and continues to cite that figure as its most recent disclosed total.
- The company says its FDA 510(k) submission for the Intelligent Fingerprinting Drug Screening System, targeting codeine detection, remains on track for the second half of calendar 2026.
- Fiscal third-quarter revenue rose 46% year-over-year to $1.06 million with gross margin crossing 50% for the first time, even as the company's 10-Q continues to disclose substantial doubt about its ability to continue as a going concern.
- Reaching this point required a clinical Cut-off Study begun in January 2026, a Method Comparison Study and Interference Study initiated in June 2026, and, by late July 2026, completed precision testing and closed-out cybersecurity items following penetration testing.
Intelligent Bio Solutions (NASDAQ:INBS) has grown its global customer base past 480 accounts and expects to file its long-awaited FDA 510(k) submission for its fingerprint-based drug screening system in the second half of 2026. With triple-digit gross-margin gains, a small but growing revenue base, and a going-concern warning still attached to its balance sheet, the medical-technology company's path into the U.S. drug-testing market remains a high-stakes balancing act.
Why INBS Is Back on Investors' Radar
Intelligent Bio Solutions Inc. (INBS), developer of a fingerprint sweat-based drug-screening platform, has spent 2026 stacking up milestones aimed at entering the U.S. drug-testing market. In a July 23, 2026 release, the company said it had resolved all cybersecurity and software review items tied to its planned FDA 510(k) submission, following independent penetration testing. Two days earlier, on July 21, 2026, it reported completing precision testing across more than 1,600 samples at three sites, another input into the submission package.
Those announcements followed a fiscal third-quarter report, issued May 13, 2026, disclosing 46% year-over-year revenue growth and gross margin above 50% for the first time. Together, the news flow points to real commercial traction outside the United States while the company finishes work required for domestic clearance. Whether that is enough to justify attention depends on how the FDA process unfolds, and whether the company can keep funding operations while it waits.
A Fingerprint-Based Alternative to Traditional Drug Testing
Intelligent Bio Solutions is a medical technology company delivering rapid, non-invasive testing. Its core product, the Intelligent Fingerprinting Drug Screening System, collects a sweat sample from a fingerprint in seconds and produces results in under ten minutes, screening for opiates, cocaine, methamphetamine and cannabis. It is marketed as a hygienic, cost-effective alternative to urine, oral fluid or blood testing for employers in safety-critical industries such as construction, mining, transportation and logistics.
Outside the U.S., where the product needs no FDA clearance, the company runs a "razor-razorblade" model: placing durable readers, then generating recurring revenue from single-use cartridges. Cartridge sales rose 59% year-over-year in the fiscal third quarter and represented 66% of total revenue, evidence of growing consumable reorders.
The Catalyst: A 510(k) Filing With a Long Runway Still Ahead
The catalyst behind renewed interest in Intelligent Bio Solutions (INBS) is the planned FDA 510(k) submission, which the company says is on track for the second half of calendar 2026. The filing targets codeine detection as its initial indication, narrower than the multi-drug panel used internationally, but one management says would open broader U.S. market access spanning workplace testing, criminal justice, pain management and substance-abuse treatment, beyond the forensic-use-only settings the technology is currently used in domestically.
Reaching this point required a clinical Cut-off Study begun in January 2026, a Method Comparison Study and Interference Study initiated in June 2026, and, by late July 2026, completed precision testing and closed-out cybersecurity items following penetration testing. Even so, a submission is not clearance: FDA timelines vary, and the company has not disclosed an expected clearance date or launch timeline.
Customer Growth and Operating Momentum
In an October 30, 2025 release covering its fiscal first quarter ended September 30, 2025, the company said it added 33 new customer accounts, a 50% increase year-over-year, bringing total active accounts to over 480 across roughly 27 to 35 countries. Its investor relations site still cites "over 480 active customer accounts" as its most recent figure; later releases have referred only generally to "hundreds of customer accounts."
Fiscal third-quarter revenue totaled $1.06 million, up 46% year-over-year. Nine-month revenue reached $3.07 million, up 39%, while nine-month gross margin improved to 49.3% from 41.3%, roughly 800 basis points, attributed to operational efficiencies, higher volumes and a new manufacturing partnership with Syrma Johari MedTech, expected to cut production costs by more than 40% annually.
Revenue Growth Meets a Persistent Cash Challenge
Despite the operating gains, Intelligent Bio Solutions remains small and loss-making. It reported a net loss of $2.86 million for the fiscal third quarter and $8.52 million for the nine months ended March 31, 2026, versus $2.54 million and $7.48 million a year earlier. As of March 31, 2026, cash and equivalents stood at $6.86 million, working capital at $5.14 million, shareholders' equity at $8.75 million and accumulated deficit at $71.06 million.
That cash position followed a $10.0 million private placement with two institutional investors, with net proceeds of $9.40 million received January 2, 2026; nine-month capital raised, net of costs, totaled $14.67 million. Even so, unaudited statements filed May 13, 2026 state management believes cash may be insufficient for the next twelve months, and these conditions "raise substantial doubt about the Company's ability to continue as a going concern." The company intends to raise more funds but acknowledges no assurance of acceptable terms.
What Could Drive the Stock From Here
Beyond the codeine filing, the company points to a validation study targeting 70% faster cartridge results, an eighth European patent grant, a UK drug-testing rollout with Bouygues UK, and a strategic alliance with Australian wearable-sensor company Vlepis Pty Ltd aimed at consumer health monitoring. Each is a potential incremental driver independent of the U.S. regulatory timeline.
Material Risks Facing Intelligent Bio Solutions
The most significant risk is financial: the going-concern disclosure means the company will likely need to raise capital again within a year, diluting shareholders given its small market capitalization and low share count post-reverse-split. Regulatory risk is substantial too: an H2 2026 timeline is company-stated, not FDA-confirmed, and the agency could request more data or extend review. The Nasdaq listing has proven fragile: a bid-price deficiency letter arrived in November 2023 alongside a stockholders'-equity notice, and another bid-price letter arrived December 15, 2025, prompting a 1-for-10 reverse split that same day; Nasdaq confirmed regained compliance on January 7, 2026. The business also remains concentrated outside the U.S. and dependent on a narrow set of industries.
Outlook
In an upside scenario, the company files its 510(k) submission in H2 2026, receives constructive FDA feedback, and keeps growing internationally while securing financing on reasonable terms. In a base case, revenue growth and margin expansion continue, but the regulatory process takes longer than hoped, requiring further capital raises. In a downside scenario, FDA review is delayed, financing becomes harder to secure, and the going-concern conditions in the latest 10-Q intensify, pressuring shareholder value. No price target or clearance timeline can be reliably predicted from currently available information.
Conclusion
Intelligent Bio Solutions Inc. (INBS) has built genuine commercial momentum outside the United States, crossing 480 active customer accounts and posting its first quarter above 50% gross margin, while pushing its FDA 510(k) submission toward a targeted filing in the second half of 2026. Whether fingerprint-based drug screening can crack the U.S. market now depends on regulatory review the company does not control, and on its ability to keep funding operations through a period its own filings describe as carrying substantial going-concern doubt.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...